drugset / Trial / NCT00002066

Double Blind Study of Thymopentin Effects on Patients With HIV-1 Infection

NCT00002066

Double-blindTreatment

Summary

Examine the ability of thymopentin (Timunox) to: Reduce the amount and/or frequency of virus isolation. Stimulate the immune system and alter the clinical findings in patients infected with HIV who do not yet have AIDS.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Thymopentin Peptide